Stocktoria
Vericel Corp VCEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1997-02-04
Vericel Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $276.3M | $237.2M | $197.5M | $164.4M | $156.2M |
| Gross profit | $205.6M | $172.1M | $135.6M | $109.8M | $106.0M |
| R&D expense | $27.6M | $24.8M | $21.0M | $19.9M | $16.3M |
| SG&A expense | $167.0M | $142.8M | $121.0M | $106.9M | $97.6M |
| Operating income | $11.0M | $4.5M | -$6.5M | -$17.1M | -$7.9M |
| Interest expense | — | — | $600,000 | $366,000 | $4,000 |
| Income tax | $859,000 | $148,000 | $814,000 | $721,000 | -$111,000 |
| Net income | $16.5M | $10.4M | -$3.2M | -$16.7M | -$7.5M |
| EPS (diluted) | $0.32 | $0.20 | $-0.07 | $-0.35 | $-0.16 |
| Operating cash flow | $51.9M | $58.2M | $35.3M | $17.7M | $29.0M |
| Free cash flow | $24.7M | -$5.8M | $15.3M | $10.1M | $21.1M |
| Cash & equivalents | $100.1M | $74.5M | $69.1M | $51.1M | $68.3M |
| Inventory | $17.6M | $17.4M | $13.1M | $16.0M | $13.4M |
| Total assets | $488.0M | $432.7M | $353.7M | $273.0M | $243.7M |
| Total liabilities | $133.3M | $140.8M | $127.7M | $80.7M | $73.2M |
| Shareholders' equity | $354.6M | $292.0M | $226.0M | $192.3M | $170.5M |
Source: SEC EDGAR filings · CIK 0000887359 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.